NCT02124512View on ClinicalTrials.gov

Blood Lipopolysaccharide (LPS) Rifaximin Study

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
ObeseInsulin ResistanceMetabolic Syndrome
Interventions
DRUG

Rifaximin SSD

Study Drug dosing will be 80 mg SSD once daily

OTHER

Placebo

80 mg placebo once daily

Trial Locations (1)

40536

University of Kentucky Center for Clinical and Translational Science, Lexington

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Philip Kern

OTHER

NCT02124512 - Blood Lipopolysaccharide (LPS) Rifaximin Study | Biotech Hunter | Biotech Hunter